

Index

A

- ADC. *See* Apparent diffusion coefficient (ADC)
- ALS. *See* Amyotrophic lateral sclerosis (ALS)
- Alzheimer's disease (AD)
 - Cho/Cr ratios, 60
 - decreased glutamate (Glu), 60
 - glial proliferation, 60
 - global cognitive functioning, 61
 - magic angle spinning ¹H MRS, 61
 - MRS metabolite ratios, 60
 - NAA/Cr, 60
- Amyotrophic lateral sclerosis (ALS)
 - brain and spinal cord, mouse, 129
 - brain imaging modalities, 124
 - brainstem, 138
 - clinical examination, 123
 - CST, 136
 - development, 123
 - diagnosis, 122, 124
 - El Escorial criteria, 132
 - etiology, 123
 - evaluation, 133
 - extra-motor brain areas, 123, 138
 - fatal disease, 141
 - FDA-approved drug, 123
 - GABA, 136
 - Glu concentration, 134
 - human, 128
 - in vivo proton MRS, 129
 - longitudinal brain MRS, 139
 - metabolite alterations, animal models, 130
 - metabolite markers, 132
 - mimic, 124
 - mIns, 136
 - mouse and rat, 128
 - MRSI data, 133
 - MRS spectra, 131
 - myoinositol levels, 130
 - oxidative stress-mediated neuronal cell death, 136
 - pathogenesis, 123
 - pathophysiological processes, 140
 - primary motor cortex, 140
 - SOD1 mice, 129
 - spinal cord, 138
 - sporadic definite, 133
 - whole-brain MRSI and T1-MRI data, 127
- Antiretroviral therapy (ART), 210
- Apparent diffusion coefficient (ADC), 202
- ART. *See* Antiretroviral therapy (ART)
- Ascorbate, 4, 5
- Astrogliosis, 203
- Ataxia, 186–194
 - advanced MRS methods, 194, 195
 - animal models
 - dominantly inherited ataxias, 186–188
 - recessively inherited ataxias, 186
 - clinical MRS
 - CCA, 188
 - dominantly inherited ataxias, 192–193
 - OPCA, 188
 - recessively inherited ataxias, 189–192
 - sporadic, 193–194
 - dominantly inherited, 182–183
 - high-magnetic-field scanners, 194
 - J-coupled metabolites, 194
 - longitudinal investigations, 194
 - magnetic resonance spectroscopy, 183–184
 - pathological classification, 180–183

Ataxia (*cont.*)
 recessively inherited, 182
 sporadic, 183
 symptoms, 180
 technical considerations, 184–186

Ataxia with oculomotor apraxia type
 2 (AOA2), 182, 192

Ataxia-telangiectasia (A-T)
 ATLD, 192
 FRDA, 182

Ataxia-Telangiectasia-Like Disorder
 (ATLD), 192

Atypical parkinsonian disorders (APD)
 corticobasal degeneration, 76
 differential MRS findings, 88–89
 DLB, 74
 manganism, 76
 MSA, 75
 PSP, 75

Autosomal recessive spastic ataxia of
 Charlevoix-Saguenay (ARSACS),
 182, 192

B

Basal ganglia, 211

BBB. *See* Blood–brain barrier (BBB)

Bioenergetics, 244, 245

Biomarker, HD, 112

Blood–brain barrier (BBB), 211

Blood-oxygen-level-dependent (BOLD), 3

BOLD. *See* Blood-oxygen-level-dependent
 (BOLD)

Brain echo-planar spectroscopic imaging, 248

Brainstem and MRS, 138

C

Cardiac PCr/ATP ratio, 191

Carr-Purcell-Meiboom-Gill (CPMG), 185

cART. *See* Combination antiretroviral therapy
 (cART)

Caudate, HD, 105–107, 113–115, 117

Central nervous system (CNS), 211

Cerebellar atrophic patterns, 183

Cerebellar syndrome, 202

Cerebrospinal fluid (CSF), 186

Chemical shift displacement error (CSDE), 20,
 21, 36

Choline, 4–6

Choline-containing compounds (tCho), 183

Clinically isolated syndrome (CIS), 162

CMV. *See* Cytomegalovirus (CMV)

CNS. *See* Central nervous system (CNS)

Coefficients of variance (CVs), 216

Combination antiretroviral therapy (cART), 211

Corticobasal degeneration, 76

Corticospinal tracts (CST)
 metabolite values, 137
 MRS, 136, 137

Cramér-Rao lower bounds (CRLB), 24

Creatine, 4–6, 245

Creutzfeldt–Jakob disease, 202

CRLB. *See* Cramér-Rao lower bounds (CRLB)

CSDE. *See* Chemical shift displacement error
 (CSDE)

Cytomegalovirus (CMV), 212

D

Degenerative brain diseases
 axon diameter and density, 3
 cerebral pathology, 2
 chronic neurodegenerative diseases, 2
 clinical outcome, 2
 demyelination, 3
 dopamine function, 4
 global and regional brain atrophy, 3
 magnetization transfer MRI, 3
 mechanistic investigations, 2
 monitors dopamine dysfunction, 4
 neurological diseases, 2
 neuronal dysfunction, 2
 NIH and Alzheimer Association
 guidelines, 3
 PET, 3
 proton (¹H) MR modalities, 3
 radionuclide imaging detects, 4
 structural MRI, 3
 subcellular and molecular levels, 3

Dementia, 60
 AD (*see* Alzheimer's disease (AD))
 disease pathology, 56–57
 DLB, 61
 FTLD, 62
 MCI, 59
 neuroimaging biomarkers, 55
 occipital lobe hypometabolism, 56
 presymptomatic Alzheimer's disease,
 57–59
 VaD, 62

Dementia with Lewy bodies (DLB), 61, 62, 74

Diffusion MRI, 3

Diffusion tensor imaging (DTI), 168, 212

Diffusion tensor spectroscopy (DTS), 168

DLB. *See* Dementia with Lewy bodies (DLB)

2D localized chemical shift correlated spectroscopy (L-COSY), 227
 Double-quantum coherence (DQC), 228
 DTI. *See* Diffusion tensor imaging (DTI)
 DTS. *See* Diffusion tensor spectroscopy (DTS)

E

EAE. *See* Experimental autoimmune encephalomyelitis (EAE)
 EBM. *See* Evidence-based medicine (EBM)
 Echo-planar spectroscopic imaging (EPSI), 43
 EDSS. *See* Expanded disability status scale (EDSS)
 Energy metabolism in HD
 ATP production, 106
 downregulation, PGC-1 α , 106
 glucose consumption, 106
 impaired glycolysis, 106
 normal and mutant alleles, 106
 TCA and respiratory chain, 107
 Epilepsy, 244
 animal models, 243
 clinical studies, 243
 Epilepsy (*see also* MR spectroscopy, epilepsy)
 focal epilepsy, 242
 medications, 242
 metabolic dysfunction, 242
 MR spectroscopy, 243
 MTLE, 242
 neocortical epilepsy, 247, 248, 251
 neurodegenerative disorder, 244
 seizure behavior, 242
 EPSI. *See* Echo-planar spectroscopic imaging (EPSI)
 Evidence-based medicine (EBM), 8
 Expanded disability status scale (EDSS), 153, 164
 Experimental autoimmune encephalomyelitis (EAE), 166
 Extracellular GABA (ecGABA), 247

F

Fatal familial insomnia (FFI), 202
 18-fluoro-deoxyglucose-PET (FDG-PET), 245
 Free induction decay (FID), 40
 Friedreich's ataxia (FRDA), 181
 1H MRS in cerebellum, 189
 1H MRS in pons and spinal cord, 190–191
 31P MRS in heart and muscle, 191
 Friedreich's ataxia rating scale (FARS), 180

Frontotemporal dementia (FTD), 57
 Frontotemporal lobar degeneration (FTLD), 62
 FTD. *See* Frontotemporal dementia (FTD)
 FTLD. *See* Frontotemporal lobar degeneration (FTLD)
 Full width at half maximum (FWHM), 44

G

Gamma-aminobutyric acid (GABA), 40, 168
 function, 246
 Gerstmann–Straussler–Scheinker (GSS), 202
 GFAP. *See* Glial fibrillary acidic protein (GFAP)
 Glial fibrillary acidic protein (GFAP), 220
 Glial/neuronal unit (“bGNU”), 245
 Glutamate, 4–6
 Glutamate and GABA, 252, 253
 Glutamate, glutamine, γ -aminobutyric acid (GABA), 184
 Glutamine, 4–6
 Glutathione, 4–6
 Glutathione (GSH), 169
 GSS. *See* Gerstmann–Straussler–Scheinker (GSS)

H

Hippocampus, 211
 HIV. *See* Human immunodeficiency virus (HIV)
 HIV encephalitis (HIVE), 218
 HIV-associated neurocognitive disorders (HAND)
 ART, 210
 cART, 211
 CD4⁺ lymphocytes, 210
 CD8-depleted macaque model, 228
 choline-containing compounds, 212
 chronic HIV infection, 225
 clinical trials, 226
 CNS, 211
 comorbidities, 226–227
 cortical and subcortical brain regions, 211
 early HIV infection, 224–225
 echo time, 213
 field strengths, 215–216
 FIV models, 218–219
 Glx levels, 213
 HIV, 210
 HIVinfected children, 227
 ipsilateral and contralateral site, 218
 Lac/Cr ratio, 213

- HIV-associated neurocognitive disorders (HAND) (*cont.*)
- LCModel, 228
 - macrophages and microglia, 211
 - metabolite concentrations, 218
 - MRS, 212
 - Myo*-inositol, 212
 - NAA/Creatine (NAA/Cr), 212
 - natural disease progression, 210
 - neuroAIDS, 218
 - neuroimaging techniques, 212
 - post mortem neuropathological studies, 211, 218
 - post post-cART, 225–226
 - ratios *vs.* absolute concentration, 217
 - SCID mouse model, 218
 - seroconversion, 210
 - single voxel *vs.* MRSI, 214–215
 - SPECT and PET, 212
 - structural neuroimaging methods, 212
 - total creatine, 213
- ¹H MRS
- GABA inhibition, 169
 - GSH, 169
 - MR scanners, 168
 - ³¹P MRS, 169
- ¹H nuclear magnetic resonance (NMR) spectroscopy, 186
- Human ataxin-1 in Purkinje cells, 187
- Human immunodeficiency virus (HIV), 210
- Huntington's disease (HD), 106–107, 112, 113
- behavioural and psychiatric disorders, 105
 - clinical MRS, 114–116
 - accurate quantification, 113
 - avoiding/correcting partial volume effects, 113
 - data acquisition techniques, 113
 - motor symptoms, 112
 - phosphorus (*see* Phosphorus MRS in HD)
 - presymptomatic and patient groups, 113
 - proton MRS (*see* Proton MRS in HD)
 - clinical utility, MRS
 - metabolic changes, 107
 - monogenic disease, 107
 - neurodegeneration, 107
 - sensitivity, 107
 - therapeutic strategies, 107
 - tracking, brain regions, 107
 - detection of metabolic changes, 117
 - molecular diagnosis, 104
 - MRS in animal models, 108–112
 - biomarker, 112
 - phosphorus (*see* Phosphorus MRS in HD)
 - proton (*see* Proton MRS in HD)
 - neuropathology, 105–106
 - ¹⁷O MRS, 117
 - pathophysiology and Energy Metabolism (*see* Energy metabolism in HD)
 - presymptomatic testing, 104
 - prevalence, 104
 - symptoms and signs, 105
 - UHDRS, 117
- I**
- Iatrogenic Creutzfeldt–Jakob disease (i-CJD), 202
- Idiopathic Parkinson's disease (IPD), 72–74, 81
- Image-selected in vivo spectroscopy (ISIS), 39, 40
- In vivo proton magnetic resonance spectroscopy (¹H MRS), 183
- International Cooperative Ataxia Rating Scale (ICARS), 180
- ISIS. *See* Image-selected in vivo spectroscopy (ISIS)
- K**
- Ketogenic diet, 243
- L**
- Lactate, 4–6
- Localization, MRS, 35–40, 42–44, 46
- MRSI
 - acceleration, acquisition schemes, 43
 - SNR, 43
 - spatial response function, 44
 - SVS, 44, 46
 - volume selection, 43
 - weighted elliptical sampling, 42
- SVS
 - ISIS, 39–40
 - PRESS, 35–38
 - spectral editing, 40
 - STEAM, 38
- M**
- Magnetic resonance spectroscopic imaging (MRSI), 185
- Magnetic resonance spectroscopy (MRS), 5, 16, 17, 19–22, 24–28, 212
 - acute lesions, 157–158

- animal handling and data acquisition
 - strategies, 22–23
- animal models, 91–95, 166–168
- chronic lesions, 158
- CIS, 162
- cognitive impairment, 164, 165
- commonly quantified metabolites, 157
- and correction factors, 81–82
- Cr and mIns, 157
- diagnosis, 161
- disability, 164
- disease progression/treatment effect, 90, 91
- fatigue, 164
- frequency and phase correction, 23
- grey matter, 159–161
- hardware requirements
 - B₀ shimming, 17
 - RF coils, 16
 - shim system, 16
- ¹H-MRS, 14, 156
- human neurodegenerative diseases, 13, 14
- increased brain iron content, 82
- in vivo ¹H MRS, mouse brain, 14, 15
- localization techniques
 - brain metabolites, 19
 - CSDE, 20
 - Eddy currents, 22
 - performance, 21–22
 - pulse sequences, ¹H MRS, 19–20
 - single-voxel ¹H MRS studies, 19
 - spatial localization, 17
 - water suppression, 21
- magnetic resonance imaging, 155, 156
- mask reproducibility, 95
- metabolic abnormalities, 77
- metabolite quantification
 - ¹H MRS spectra, 24
 - macromolecule background, 26
 - methods, 24–26
 - neurochemical profiling, 28
 - referencing, 26–27
 - relaxation, 27–28
- metabolites and neurotransmitters, 78
- mIns/NAA ratio, 163
- monitoring treatment response, 163–164
- MR spectra, 155
- neurodegeneration, 163
- normal appearing white matter, 158, 159
- in PDS, 80
- quantification, 51–52
- quantitative MRI techniques, 155
- residual Eddy currents, 23–24
- RIS, 161, 162
- RRMS, 162–163
- spinal cord, 165
- study population heterogeneity, 82
- techniques and processing tools, 14
- volume loss, neurodegeneration, 95
- Manganese-enhanced MRI (MEMRI), 3
- Manganism, 76
- MAP2. *See* Microtubule-associated protein 2 (MAP2)
- MCI. *See* Mild cognitive impairment (MCI)
- Medial temporal lobe epilepsy, 246–247
- Microtubule-associated protein 2 (MAP2), 222
- Mild cognitive impairment (MCI), 59
- Mitochondrial disease, 244
- Motor cortex, 131–136
- MRS
 - ALS and UMN diseases, 133
 - ALS patients, 131
 - clinical assessment data, 133
 - Cre, 132
 - CST, 134
 - GABA, 136
 - glutamate-induced excitotoxicity, 134
 - GSH, 136
 - intracranial corticospinal tracts, 135
 - metabolite markers, 132
 - myoinositol concentration, 136
 - NAA, 131–133
 - PRESS SVS sequence, 132
 - single-slice MRSI approaches, 132
 - whole-brain MRSI, 133
- Motor neuron diseases (MND), 123, 124, 126–141
 - adult-onset diseases, 122
 - ALS, 122, 123
 - anatomical locations, 122
 - central nervous system, 122
 - LMN, 122
 - MRS, 131–136
 - animal model, 128–130
 - brain, 131–138
 - brainstem, 138
 - calculation, metabolite relaxation times, 139
 - cerebral metabolites, 124
 - concentration differences, 140
 - conventional, 140
 - conventional, CST and motor cortex, 124
 - corticospinal tracts, 136–137
 - deficits in LMN function, 124
 - detection, non-motor brain regions, 126
 - development and standardization, 141
 - effects of therapeutics, 139

- Motor neuron diseases (MND) (*cont.*)
 extra-motor brain regions, 138
 longitudinal studies, 139
 metabolite quantitative data, 127
 motor cortex (*see* Motor cortex)
 quality of data, 140
 spectroscopic data, 126
 spinal cord, 138
 whole-brain level, 140
 whole-brain MRS data acquisition
 method, 126, 140
 UMN, 122
- MPTP model, 93, 94
- MR spectroscopic imaging (MRSI), 81
 acquisition schemes, 43
 medial temporal lobe epilepsy, 246–247
 NAA/Cr, 245
 seizure localization, 255
 SNR, 43
 spatial response function, 44
 volume selection, 43
 weighted elliptical sampling, 42
- MR spectroscopy, 243
- MR spectroscopy, epilepsy
 animal model, 253
 creatine, 245
 FDG-PET, 245
 MRSI, 244, 245
 NAA, 244
- MTLE, 242
- Multiple sclerosis (MS)
 aetiology and pathophysiology, 152
 autoimmune inflammatory disorder, 153
 brain and spinal cord, 151
 CD4+ T cells and B-lymphocytes, 153
 CD8+ T lymphocytes, 153
 classification, 152
 EDSS, 153
 grey matter, 154–155
 PPMS, 153
 RRMS, 152
 sex-linked environmental factor, 152
 SPMS, 152
 white matter, 154
- Multiple system atrophy (MSA), 75,
 181, 183, 194
- Myoclonus, 202
- Myo-inositol, 4–6
- N**
- N*-acetylaspartate (NAA), 5, 212, 244
- Neocortical epilepsy, 247
 bGNU parameter, 251
 data, patient, 250
 NAA/Cr, 251
 seizure onset, 247, 248
 semiology, 249
- Neurodegeneration (NAA), 188
- Neurodegenerative diseases
 biomarkers and surrogate markers, 5
 CT or MRI evaluation, 5
 data quality, 6
 high-quality MRS data, 6
 macrostructural changes, 5
 MR technologist friendly, 6
 MRS, 5
 spectral fitting, 7
 structural MRI and clinical measures, 2
 3 T spectra, 6
 vendor-provided localization sequences, 6
 volume of interest (VOI), 7
- Neurodegenerative disorder, 244
- Neuroinflammation, 212, 218, 226
- Neuromyelitis optica (NMO), 161
- Neurosyphilis, 212
- Nigrostriatal dopaminergic degeneration,
 IPD, 83
- Nucleoside reverse transcriptase inhibitors
 (NRTIs), 226
- O**
- 6-OHDA, 92
- Olivopontocerebellar atrophy (OPCA), 181, 188
- Outer volume suppression (OVS), 48
- P**
- Paraquat, 94
- Parkinsonian disorders (PDS), 83–86
 bradykinesia (slowness of movement), 72
 brain regions, 80
 clinical features, 72
 glutamate and GABA, 86
¹H MRS studies
 basal ganglia, 83–85
 cortical brain regions, 85, 86
 metabolite changes, IPD vs. controls, 83
 MPTP metabolism and toxicity,
 dopaminergic neurons, 93
 muscle stiffness, 72
 normal and abnormal circuitry, basal
 ganglia, 79
 phosphorus (³¹P) MRS, 87, 88
 tremor and postural instability, 72
- Partial Least Squares Discriminant Analysis
 (PLSDA), 111

- PET. *See* Positron emission tomography (PET)
- Phosphocreatine (PCr), 191
- Phosphorus MRS in HD, 78, 110–112
- animal models
 - cytoplasmic alkalization, 111
 - energy metabolism, 112
 - human occipital measures, 110
 - metabolomic characterization, 110
 - mice, 110
 - R6/2 and Q111 mice, 110
 - brain, 115
 - CSF, 115
 - Pi/PCr and Pi/ATP, 116
 - ³¹P NMR spectrum, occipital cortex, 116
- Pilocarpine rat model, 254
- PML. *See* Progressive multifocal leukoencephalopathy (PML)
- Point-resolved spectroscopy (PRESS), 35
- CSDE, 36, 37
 - LASER, 37
 - localization, 35
 - magnetization, 36
 - RF pulses, 36
 - semi-LASER, 38
 - volume of interest, 36
- Polyglutamine-related SCA, 182
- Positron emission tomography (PET), 3
- Posterior cingulate gyrus, 58, 59
- Posterior cingulate voxel, 60–62
- PPMS. *See* Primary progressive MS (PPMS)
- PRESS. *See* Point-resolved spectroscopy (PRESS)
- Presymptomatic Alzheimer's disease, 57–59
- Primary generalized epilepsy, 242
- Primary progressive MS (PPMS), 153
- Prion diseases
- ADC and NAA/Cr ratios, 206
 - astrogliosis, 203
 - axonal and dendritic processes, 203
 - cerebellum, 206
 - Creutzfeldt–Jakob disease, 202
 - global neuroimaging protocol, 202
 - lentiform and caudate nuclei, 202
 - myo-inositol/NAA ratios, 204
 - N*-acetylaspartate, 203
 - neurodegenerative disorders, 201
 - pathogenicity, 201
 - single voxel acquisition, 202
 - spectroscopy, 206
- Prion-related protein (PrP), 201
- Progressive agrammatic/nonfluent aphasia (PNFA), 57
- Progressive multifocal leukoencephalopathy (PML), 212
- Progressive supranuclear palsy (PSP), 75
- Progressive Supranuclear Palsy Rating Scale (PSPRS), 75
- Proton MRS in HD, 108–111
- animal models
 - assessment, metabolite changes, 109
 - cortical and striatal changes, 109
 - disease progression, 108
 - genetic mouse models, 108
 - PLSDA, 111
 - R6/2 and Q111 mice, 110
 - systemic injections, metabolic inhibitors, 108
 - toxic structure, 108
 - treatments, 108
 - young Q111 mice, 110
 - brain metabolites, 125
 - caudate, 114
 - cohorts of presymptomatic individuals, 115
 - discrete anatomical regions, 128
 - echo time, 114
 - ¹H MRS, 114
 - metabolite ratios, 114
 - neurodegeneration and gliosis, 114
 - putamen, 114
- PrP. *See* Prion-related protein (PrP)
- Purkinje cells, 182
- Putamen, HD, 105, 106, 113–115
- R**
- Radiologically isolated syndrome (RIS), 161, 162
- Reduced tNAA-to-tCr ratio (tNAA/tCr), 189
- Relapsing–remitting MS (RRMS), 152
- Relaxation Times of Brain Metabolites, 139
- Resting state functional MRI (rsfMRI), 3
- Rhesus macaque, 216, 219, 221, 222
- RIS. *See* Radiologically isolated syndrome (RIS)
- Rotenone, 94
- RRMS. *See* Relapsing–remitting MS (RRMS)
- S**
- Scrapie, 203
- Secondary progressive MS (SPMS), 152
- Semantic variant primary progressive aphasia (svPPA), 57
- Semi-LASER, 185
- Semiology, 249
- Severe combined immunodeficient (SCID), 218
- Signal-to-noise ratio (SNR), 16, 168, 185, 214
- Simian immunodeficiency virus (SIV), 213
- antiretroviral therapy, 219

- Simian immunodeficiency virus (SIV) (*cont.*)
- astrocytosis, 220
 - CART and minocycline, 222–223
 - CD4⁺ T lymphocytes, 219
 - choline, 220
 - chronic SIV Infection, 221
 - CNS disease progression, 219
 - glial-cell activation and proliferation, 220
 - Myo*-inositol levels, 220
 - NAA/Cr, 219
 - neuroinvasion, 219
 - SIV⁺/CD8⁻ animals, 221–222
- Single-voxel spectroscopy (SVS)
- ISIS, 39–40
 - PRESS, 35–38
 - spectral editing, 40
 - STEAM, 38
- SIV. *See* Simian immunodeficiency virus (SIV)
- SIV encephalitis (SIVE), 221
- SNR. *See* Signal-to-noise ratio (SNR)
- SPECIAL. *See* Spin echo full intensity acquired localization (SPECIAL)
- Spectral editing, 40
- Spectroscopy pulse sequences, 47
- Spin echo full intensity acquired localization (SPECIAL), 20, 40
- Spinal cord, 165
- and MRS, 138
- Spinocerebellar ataxia
- AOA2, 182
 - degeneration, 181
 - SCAR1, 182
 - vestibular, 181
- Spinocerebellar ataxia 5 (SCA5), 181
- Spinocerebellar degeneration, 181
- SPMS. *See* Secondary progressive MS (SPMS)
- Standard proton MRS (¹H MRS) techniques, 77
- Stimulated echo acquisition mode (STEAM), 19, 38
- Susceptibility-weighted imaging, 4
- T**
- Technical challenges and solutions,
- MRS, 33, 51–52
 - calibrations, 50
 - localization (*see* Localization, MRS)
 - magnetic field homogeneity, 49
 - MRS quantification
 - corrections, 52
 - processing and fitting of spectra, 51–52
 - outer volume suppression, 48–49
 - sensitivity, 32–33
 - water suppression, 46–47
- Theiler's murine encephalomyelitis virus (TMEV) infection, 166
- TMEV infection. *See* Theiler's murine encephalomyelitis virus (TMEV) infection
- Toxoplasmosis, 212
- Transgenic SCA1 model, 187
- U**
- Unified HD Rating Scale (UHDRS) scores, 117
- V**
- VaD. *See* Vascular dementia (VaD)
- Variant Creutzfeldt–Jakob disease (v-CJD), 202
- Vascular dementia (VaD), 62
- v-CJD. *See* Variant Creutzfeldt–Jakob disease (v-CJD)
- Video-EEG, 246
- Vmax(ATP), 191
- Volume of interest (VOI), 16, 163
- W**
- Water suppression, 17, 19